Doctor of Osteopathy Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Jaskiran Vidwan

Neurology Rockville, MD Doctor of Osteopathy

NPI 1851547756 CMS profile 387577

1201 Seven Locks Rd, Suite 101, Rockville, MD 20854

Open in the dashboard

General payments

$14,217

149 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Jaskiran Vidwan of Rockville, MD is reported in the CMS Open Payments database as having received $14,217 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $12,307 56
2019 General $1,910 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaskiran Vidwan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jaskiran Vidwan were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jaskiran Vidwan Neurology median Middle half National median
2019 $1,910 $474 $118–$2,177 $163
2020 $12,307 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Allergan Inc. $11,731 22 payments
  2. Amgen Inc. $850 31 payments
  3. Teva Pharmaceuticals USA, Inc. $448 20 payments
  4. Upsher-Smith Laboratories LLC $323 21 payments
  5. Novartis Pharmaceuticals Corporation $174 8 payments
  6. Bausch Health US, LLC $120 8 payments
  7. Avanir Pharmaceuticals, Inc. $115 7 payments
  8. Lilly USA, LLC $106 7 payments
  9. Zyla Life Sciences $88 7 payments
  10. ASSERTIO THERAPEUTICS, Inc. $77 5 payments
  11. Other $185 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,620 6 payments
  2. Food and Beverage $2,977 141 payments
  3. Travel and Lodging $620 2 payments
Products named General payments · program years 2019–2020
  1. UBRELVY $11,625 16 payments
  2. AIMOVIG $1,024 39 payments
  3. Ajovy $393 16 payments
  4. Zembrace SymTouch Sumatriptan Injection $301 20 payments
  5. Tosymra Sumatriptan Nasal Spray $301 20 payments
  6. QUDEXY XR Topiramate Extended Release Capsules $297 19 payments
  7. MIGRANAL $120 8 payments
  8. NUEDEXTA $115 7 payments
  9. EMGALITY $106 7 payments
  10. BOTOX $94 5 payments
  11. Other $532 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,961

Median for Neurology: 833

Drug cost

$710,067

Median for Neurology: $202,670

Branded share of claims

45.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 119 $171,269
Ubrelvy Ubrogepant Brand 101 $114,226
Aimovig Autoinjector Erenumab-Aooe Brand 117 $110,768
Emgality Pen Galcanezumab-Gnlm Brand 115 $97,513
Qulipta Atogepant Brand 79 $92,445
Ajovy Autoinjector Fremanezumab-Vfrm Brand 63 $61,828
Reyvow Lasmiditan Succinate Brand 26 $19,751
Dihydroergotamine Mesylate Generic 14 $11,516
Gabapentin Generic 169 $3,522
Naratriptan Hcl Generic 116 $3,363

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$25,716

Medicare's payments for the services billed

Medicare patients

180

Average age 68

Services billed

481

129 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 57%
Depression 39%
Diabetes 28%
Osteoporosis 20%
Chronic kidney disease 19%
Ischemic heart disease 18%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record